There is already much Australian interest in purchasing one of the suites on Ulyssia, which range in price from €10m to €100m ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Germany's Merck KGaA expects annual sales to be at the lower half of ... according to consensus estimates provided by the company. Earnings before interest taxes depreciation and amortization before ...

Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

German companies including Merck and ZEISS expressed strong confidence and high hopes for the Chinese market at the China ...